Search Results for "diagnosis"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
ILLUMINATE Clinical Trial Program Overview
This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.
This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
ATTR Screening and Carrier
ATTR Screening and Carrier
ATTR Screening and Carrier
